Media Articles Related to Minoxidil
Source: MedicineNet Chronic Obstructive Pulmonary Disease (COPD) Specialty [2013.11.25]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/25/2013 12:00:00 AM
Increased risk of alcohol-related hypertension in individuals who flush after drinking
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2013.11.21]
Excessive drinking is a known risk factor for hypertension. Drinking that results in facial flushing indicates high sensitivity or even intolerance to alcohol. A study of the relationship between drinking and these two conditions has found that drinking-related hypertension has a lower threshold value and higher risk in flushers than in non-flushers.
Some allergy suffers with hypertension may be at increased risk for severe reaction
Source: Allergy News From Medical News Today [2013.11.12]
Oral allergy syndrome sufferers that take high blood pressure medications may experience extreme facial swelling and difficulty breathing the next time they bite into a juicy apple.
In low-income urban neighborhoods the rates of diabetes, hypertension, heart disease and stroke are much higher
Source: Hypertension News From Medical News Today [2013.11.07]
There is more to the cost of living in a food desert than higher prices for the few fruits and vegetables sold nearby, according to a study by an Indiana University-Purdue University Indianapolis researcher and the Marion County Public Health Department.
Further positive Opsumit (macitentan) data in pulmonary arterial hypertension presented at CHEST 2013
Source: Hypertension News From Medical News Today [2013.10.31]
Actelion (SIX: ATLN) has announced that following the recent FDA approval and positive CHMP opinion for macitentan (Opsumit®) in pulmonary arterial hypertension (PAH), further positive data on the efficacy of macitentan from the SERAPHIN study were presented at CHEST 2013 in Chicago, USA (26-31 October 2013).
Published Studies Related to Minoxidil
Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men. [2009.08]
Minoxidil is efficacious in inducing hair growth in patients with androgenetic alopecia by inducing hair follicles to undergo transition from the early to late anagen phase... Our findings confirmed the superiority of 5% topical minoxidil to 1% topical minoxidil in treating Japanese men with androgenetic alopecia.
A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. [2007.11]
BACKGROUND: An alternative to currently marketed topical minoxidil solutions is desirable. OBJECTIVE: To assess the efficacy and safety of a new 5% minoxidil topical formulation in a propylene glycol-free foam vehicle in men with androgenetic alopecia (AGA)... CONCLUSIONS: We believe that 5% MTF is a safe and effective treatment for men with AGA.
A randomized, placebo-controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. [2007.01]
Minoxidil is effective in inducing hair growth in patients with androgenetic alopecia by stimulating hair follicles to undergo transition from early to late anagen phase. However, there have been no controlled studies of topical minoxidil in Asian women... The patients tolerated treatment with 1% topical minoxidil well without significant adverse effects.
K+ channel activation with minoxidil stimulates nasal-epithelial ion transport and blunts exaggerated hypoxic pulmonary hypertension. [2006.03]
Increased pulmonary capillary pressure and inhibition of alveolar Na+ transport putatively contribute to the formation of pulmonary edema in alveolar hypoxia such as at high altitude. Since both events might be linked to the inhibition of K+ channels, we studied whether in vivo application of minoxidil, a stimulator of ATP-gated K channels (K+ ATP channel activator) prevents both effects...
Treatment of anal fissures using a combination of minoxidil and lignocaine: a randomized, double-blind trial. [2005.07]
AIM : Anal fissures are associated with hypertonia of the internal anal sphincter and pain. We evaluated the efficacy of local application of a combination of minoxidil and lignocaine in healing anal fissures... CONCLUSION: Combination treatment with minoxidil and lignocaine helps in faster healing of anal fissures and provides better symptomatic relief than either drug alone.
Clinical Trials Related to Minoxidil
Clinical Trial in Females With Female Pattern Hair Loss [Recruiting]
This is a year-long clinical trial to evaluate the effectiveness and safety in women with
Female Pattern Hair Loss (FPHL), comparing a new 5% minoxidil topical foam (MTF) formulation
applied once a day versus the 2% minoxidil topical solution (MTS) applied twice a day.
This clinical trial will use a standard measurement called Target Area Hair Count (TAHC) to
evaluate if there is a change in the number of hairs in the area being examined after using
the product for 24 weeks (and also after using the product for 12 Weeks).
This trial will determine if the benefit of using either study product outweighs the risks.
Efficacy and Safety Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Androgenetic Alopecia [Recruiting]
5% Minoxidil lotion was approved for using to stimulate hair growth in male androgenetic
alopecia by US FDA science 1988. The mechanism of action still unclear. In general the 5%
Minoxidil in solution is the first choice preparation for treatment, therefore allergic
contact dermatitis to solution was report up to 5. 7% (Ebner H. et al,1995). Propylene glycol
which is the main solvent of these solution, was the main responsible to allergic contact
dermatitis with positive patch test up to 81. 8% (Friedman ES. et al. 2002) One of the
alternative solution using butylene glycol as the solvent was invented to solve the problem.
In Siriraj hospital the investigators using this new solvent and made our in house product
called 5% Minoxidil milky lotion. However the efficacy and safety of the new solution have
not been investigated. This study is conducted to evaluated efficacy and safety of 5%
Minoxidil milky lotion compare with the classic solution in male androgenetic alopecia.
Efficacy of Minoxidil in Children With Williams-Beuren Syndrome [Recruiting]
The Williams-Beuren syndrome (WBS) is a sporadic congenital disorder characterized by a
multisystem developmental impairment. This syndrome is caused by a microdeletion in
chromosome 7q11. 23 that encompasses loss of the elastin locus.
Elastin, which is part of the extracellular matrix, controls proliferation of vascular
smooth muscle cells (VSMCs) and stabilizes arterial structure. Loss of elastin gene in WBS
patients has been claimed to provide a biological basis for the abnormal elastic fibre
properties leading to cardiovascular abnormalities like supravalvular aortic stenosis
(SVAS), hypertension, arteriosclerosis and stenosis in more than 50% of WBS children.
These cardiovascular pathologies result in important consequences and neither curative nor
preventive medicinal treatments exist at this time. Surgery is needed in more than half
cases, while it is often leading to complications.
Minoxidil is a well-known antihypertensive drug used in adults and children. Furthermore,
according to animal studies, minoxidil seems to increase arterial elastin content by
decreasing elastase activity in these tissues. Other data demonstrate that minoxidil
specifically stimulate elastin synthesis.
Working Hypothesis: If insufficient elastin synthesis leads to vascular complications and
arterial hypertension in children with WBS, restoration of sufficient quantity of elastin
should then result in prevention or inhibition of vascular malformations and improvement in
arterial tension. Therefore, as a pharmacological agent capable to stimulate elastin
expression, minoxidil might be a useful drug for the treatment of abnormal elastin
metabolism in WBS children.
Objective: To evaluate the efficacy of minoxidil on cardiovascular structure in children with
Williams Beuren syndrome.
Methodology: randomized controlled trial on two parallel group (23 patients in each arm)
Main criterion: variation of carotid Intima-media thickness (IMT) before and after 12 months
of treatment with Minoxidil versus placebo Secondary intermediate criteria of the vascular
properties are arterial stiffness, cardiac and renal stenosis, arterial tension.
Total study duration: 30 months including a 12 month-recruitment period
Minoxidil 2% for Enhancement of Eyebrows [Not yet recruiting]
The purpose of the study is to compare minoxidil 2% versus placebo in enhancement of
Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients [Recruiting]
This study aims to investigate the effectiveness and safety of mesotherapy for the treatment
of female pattern alopecia.
- Sixty female subjects between 18 and 65 years diagnosed with female pattern hair loss
will undergo mesotherapy sessions weekly for ten weeks.
- One group will receive 0. 5%/2ml minoxidil application and a control group will receive
application of placebo (saline 0. 9%).
- Biopsy of the scalp, trichogram and trichoscopy (Fotofinder) will be performed before
and 08 weeks after treatment as a method objective evaluation of the response
Reports of Suspected Minoxidil Side Effects
Wrong Drug Administered (23),
Toxicity TO Various Agents (12),
Hypertension (11), more >>